Known targets — ChEMBL curated mechanism
ADORA1ADORA2AADORA2BADORA3PDE3APDE3BPDE4APDE4BPDE4CPDE4D
The experimentally established mechanism targets of Glutaral. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLRA1 | P23415 | 1/20 | 0.56 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.56 |
| ▸ | OR51E2 | Q9H255 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | GABRR1 | P24046 | 3/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.38 |
| ▸ | BLM | P54132 | 3/20 | 0.38 |
| ▸ | THRB | P10828 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.38 |
| ▸ | GABRR3 | A8MPY1 | 2/20 | 0.38 |
| ▸ | GABRR2 | P28476 | 2/20 | 0.38 |
| ▸ | GABRP | O00591 | 1/20 | 0.38 |
| ▸ | GABRD | O14764 | 1/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | GABBR2 | O75899 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL27653347 | 0.82 | HIF1A (0.62) | OR51E2HIF1AGABRR1TSHRLMNA | |
| Succinic Acid SCHEMBL27673327 | 0.82 | HIF1A (0.62) | OR51E2HIF1AGABRR1TSHRLMNA | |
| Glutaral SCHEMBL9577814 | 0.82 | HIF1A (0.62) | GLRA1SLC6A9OR51E2HIF1ATSHR | |
| Succinic Acid SCHEMBL28876312 | 0.82 | HIF1A (0.62) | OR51E2HIF1AGABRR1TSHRLMNA | |
| Glutaral SCHEMBL9500026 | 0.82 | HIF1A (0.71) | HIF1ATSHRLMNAMAPTCYP2D6 | |
| Glutaral SCHEMBL5868481 | 0.82 | — | — | |
| Glutaral SCHEMBL8758361 | 0.79 | HIF1A (0.67) | OR51E2HIF1ATSHRLMNABLM | |
| Glutaral SCHEMBL28754492 | 0.79 | HIF1A (0.67) | OR51E2HIF1ATSHRLMNAMAPT | |
| Glutarate SCHEMBL5443883 | 0.78 | SLC22A6 (0.61) | HIF1AGABRR1TSHRLMNABLM | |
| Adipic Acid SCHEMBL28886291 | 0.78 | LMNA (0.61) | HIF1ATSHRLMNABLMKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023230008-A1 | METHODS AND COMPOSITIONS FOR A UNIVERSAL AND LONG-LASTING VACCINE | ZHANG GONGYI (US) | 2023-11-30 | — | — | WO | disclosed |
| US-11690917-B1 | Methods and compositions for a universal and long-lasting vaccine | ZHANG GONGYI (US) | 2023-07-04 | — | — | US | disclosed |
| EP-1315517-B1 | MIMETIC PEPTIDES FOR EPITOPE OF APOLIPOPROTEIN B-100, CONCATEMER AND MODIFIED PEPTIDES THEREOF, AND THE VACCINE COMPOSITION COMPRISING THE SAME | KIM HYO JOON (KR) | 2010-10-20 | — | — | EP | disclosed |
| CN-1231262-C | Mimetic peptides for epitope of apolipoprotein B-100, concatemer and modified peptides, and vaccine composition comprising same | KIM HYO JOON (KR) | 2005-12-14 | — | — | CN | disclosed |
| CN-1392798-A | Mimetic peptides of epitope of apolipoprotein B-100, concatemer and modified peptide thereof, and vaccine composition containing the same | HYO-JOON KIM (KR) | 2003-01-22 | — | — | CN | disclosed |
| WO-2002072622-A2 | VACCINE ANTIGENS AGAINST INFECTION BY CHLAMYDIA TRACHOMATIS | YABA LIMITED (GB) | 2002-09-19 | — | — | WO | disclosed |
| WO-2002065129-A2 | EPITOPIC SEQUENCES FOR DIAGNOSING INFECTION BY CHLAMYDIA TRACHOMATIS | YABA LIMITED (GB) | 2002-08-22 | — | — | WO | disclosed |
| EP-0327801-A1 | HIV-2-type retroviruses of primates, vaccines, diagnostic and pharmaceutical compositions | DEUTSCHES PRIMATENZENTRUM GESELLSCHAFT MBH (DE) | 1989-08-16 | — | — | EP | disclosed |
| WO-1989006276-A2 | HIV-2-TYPE RETROVIRUSES OF PRIMATES, VACCINES, DIAGNOSTIC AND PHARMACEUTICAL COMPOSITIONS | DPZ DEUTSCHES PRIMATENZENTRUM GESELLSCHAFT MBH (DE) | 1989-07-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11690917-B1 | Methods and compositions for a universal and long-lasting vaccine | PRNP, SARS1, CD81 | GLRA1 2188/4885SLC6A9 4826/4885OR51E2 1198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.